XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (3,955,918) $ (20,820,853)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,691,435 4,158,270
Stock compensation 831,823 1,232,050
Gain on sale of real estate assets, net (5,078,302) (3,191,149)
Impairment of goodwill and real estate assets 4,427,245 893,939
Amortization of financing costs 201,500 286,491
Amortization of below-market leases (3,509) (3,731)
Straight-line rent adjustment 41,733 (113,491)
Changes in operating assets and liabilities:    
Other assets 294,586 158,524
Accounts payable and accrued liabilities (500,641) (784,313)
Accrued real estate taxes (514,848) (296,168)
Net cash used in operating activities (380,224) (658,434)
Cash flows from investing activities:    
Real estate acquisitions (9,444,465) (9,729,351)
Additions to buildings and tenant improvements (2,178,973) (1,939,641)
Proceeds from sale of marketable securities 13,990 60,467
Proceeds from sales of real estate, net 23,043,395 22,273,254
Net cash provided by investing activities 11,433,947 10,664,729
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 18,942,396 13,602,291
Payment of debt issuance costs (333,838) (210,661)
Repayment of mortgage notes payable (27,142,992) (19,072,175)
Payment of deferred offering costs (79,170) 0
Distributions to noncontrolling interests (507,435) (3,283,899)
Contributions from noncontrolling interests 0 200,000
Dividends paid to Series D Preferred Stockholders (1,724,850) (1,651,292)
Net cash used in financing activities (11,087,304) (9,317,275)
Net (decrease) increase in cash equivalents and restricted cash (33,581) 689,020
Cash, cash equivalents and restricted cash - beginning of period 8,036,496 6,510,428
Cash, cash equivalents and restricted cash - end of period 8,002,915 7,199,448
Supplemental disclosure of cash flow information:    
Income taxes paid 46,511 71,546
Non-cash investing activities:    
Paid building and tenant improvements from prior year (207,847) (295,567)
Unpaid building and tenant improvements 140,135 30,204
Private warrants from Conduit Pharmaceuticals 0 642,600
Non-cash financing activities:    
Unpaid debt issuance costs 85,164 0
Issuance of Series A Common Stock for minority interest 0 1,052,579
Dividends payable - Series D Preferred Stock 190,393 195,310
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid-mortgage notes payable 4,540,090 4,064,414
Common Class A [Member]    
Cash flows from financing activities:    
Issuance of Series A Common Stock, net of offering costs 1,671,463 0
Repurchase of Series A Common Stock, at cost (1,585,091) (97,394)
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Issuance of Series A Common Stock, net of offering costs 0 1,195,855
Repurchase of Series D Preferred Stock, at cost (327,787) 0
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Net loss (gain) in fair value marketable securities 184,672 17,821,437
All Other Than Conduit [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Net loss (gain) in fair value marketable securities $ 0 $ 560